Accepted Article This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/phar.1888 This article is protected by copyright. All rights reserved. Received Date : 08-Jun-2016 Revised Date : 23-Sep-2016 Accepted Date : 24-Sep-2016 Article type : Original Research Article Retrospective evaluation of postoperative adverse drug events in patients receiving rivaroxaban following major orthopedic surgery compared to standard therapy in a community hospital Nicole E. Cieri, 1,2 Kristen Kusmierski, 2 Cynthia Lackie, 2 August Van Opdorp, 2 Amany Hassan 1 1 D’Youville College School of Pharmacy 2 Millard Fillmore Suburban Hospital Pharmacy Address for Correspondence: Nicole E. Cieri cierin@dyc.edu D’Youville College School of Pharmacy 320 Porter Avenue Buffalo, NY 14201 Key Words: Rivaroxaban, Orthopedic Surgery, Bleeding, Warfarin, Enoxaparin, Anticoagulation, Venous Thromboembolism The authors have received no support for this research in the form of grants, equipment or drugs. American College of Clinical Pharmacy Annual Meeting October, 2014 Poster Presentation October 12-15 th , 2014 Austin Convention Center, Austin, Texas Abstract Study Objectives: To evaluate the occurrence of bleeding and venous thromboembolic (VTE) events in patients receiving rivaroxaban, warfarin, or warfarin with the addition of enoxaparin during the immediate post-operative period following major orthopedic surgery. Methods: Patients older than 18 years who received at least one dose of rivaroxaban the morning following surgery, adjusted dose warfarin, or adjusted dose warfarin with the addition of enoxaparin for VTE prophylaxis following major orthopedic surgery between October 1, 2011 and February 28, 2015 were included. Data collected from the electronic health record included patient demographics,